The overall goal of this Program Project is to elucidate the mechanistic basis of a novel group of recessively inherited forms of Osteogenesis Imperfecta (OI) or brittle bone disease that is based on alterations in the post-translational modification and trafficking of collagen. After twenty years where the only identifiable genetic basis of 0I has been structural mutations in type I collagen (encoded by C0L1A1 and C0L1A2 genes), we and others have shown that mutations in components of two complexes (i.e., the prolyl 3- hydroxylase and the FKBP10/HSP47 complexes) required for collagen processing account for up to 10% of cases. More importantly, they identify a potentially novel mechanism for connective tissue disease and underscore the importance of poorly understood but highly conserved evolutionary post-translational mechanisms. Still despite the well documented biochemical activities of these complexes, it has been difficult to clinically distinguish the dominant and recessively inherited forms of 0I. With bone fragility and abnormal connective tissue as the clinical endpoints, we hypothesize that these mutations ultimately lead to common pathogenic mechanisms that integrate cellular, matrix, and signaling defects that ultimately lead to the clinical phenotype. We propose to test this hypothesis by combining genetic, cell biological, and biochemical approaches to analyze novel mouse mutants and human tissues. These approaches will be encompassed by three projects: Project 1 led by Dr. Brendan Lee will be focused on the mouse and human genetic study of the P3H complex. Project 2 led by Drs. Deborah Krakow and Dan Cohn will be focused on mouse and human genetic, and cell biology study of the FKBP10 complex, and Project 3 led by Drs. David Eyre will focus on biochemical analyses of novel mouse and human models of OI and the requirement of prolyl 3-hydroxylation from the collagen perspective. The human genetic studies will supported by the Genomics Core led by Dr. D. Cohn. The implementation and integration of the work will be supported by Dr. B. Lee in the Administrative Core.

Public Health Relevance

Osteogenesis Imperfecta or brittle bone disease is the most common genetic cause of bone fragility in children. We and others have recently shown that there are many different genetic causes. This work will identify the common mechanisms by which mutations cause the clinical condition. In so doing, we hope to identify new therapies and diagnostic tools for distinguishing these conditions.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHD1)
Program Officer
Javois, Lorette Claire
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
Schools of Medicine
United States
Zip Code
Machol, Keren; Jain, Mahim; Almannai, Mohammed et al. (2016) Corner fracture type spondylometaphyseal dysplasia: Overlap with type II collagenopathies. Am J Med Genet A :
Grafe, Ingo; Alexander, Stefanie; Yang, Tao et al. (2016) Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta. J Bone Miner Res 31:1030-40
Rajagopal, Abbhirami; Homan, Erica P; Joeng, Kyu Sang et al. (2016) Restoration of the serum level of SERPINF1 does not correct the bone phenotype in Serpinf1 null mice. Mol Genet Metab 117:378-82
Lindert, Uschi; Cabral, Wayne A; Ausavarat, Surasawadee et al. (2016) MBTPS2 mutations cause defective regulated intramembrane proteolysis in X-linked osteogenesis imperfecta. Nat Commun 7:11920
Hosseininia, S; Weis, M A; Rai, J et al. (2016) Evidence for enhanced collagen type III deposition focally in the territorial matrix of osteoarthritic hip articular cartilage. Osteoarthritis Cartilage 24:1029-35
Heard, Melissa E; Besio, Roberta; Weis, MaryAnn et al. (2016) Sc65-Null Mice Provide Evidence for a Novel Endoplasmic Reticulum Complex Regulating Collagen Lysyl Hydroxylation. PLoS Genet 12:e1006002
Lietman, Caressa D; Marom, Ronit; Munivez, Elda et al. (2015) A transgenic mouse model of OI type V supports a neomorphic mechanism of the IFITM5 mutation. J Bone Miner Res 30:489-98
Patel, R M; Nagamani, S C S; Cuthbertson, D et al. (2015) A cross-sectional multicenter study of osteogenesis imperfecta in North America - results from the linked clinical research centers. Clin Genet 87:133-40
Lu, Linchao; Harutyunyan, Karine; Jin, Weidong et al. (2015) RECQL4 Regulates p53 Function In Vivo During Skeletogenesis. J Bone Miner Res 30:1077-89
Posey, Jennifer E; Burrage, Lindsay C; Campeau, Philippe M et al. (2015) Adult presentation of X-linked Conradi-Hünermann-Happle syndrome. Am J Med Genet A 167:1309-14

Showing the most recent 10 out of 66 publications